137862-87-4

Basic information

• Product Name: valsartan
• Synonyms: D-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI);(R)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid;ent-Valsartan;D-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]- 4-yl]methyl]-;(S)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine;ent-Valsartan：(R)-N-Valeryl-N-([2'-(1-H-tetrazole)-5-yl)-biphenyl-4-yl]-Methyl)-valine;(R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-Methyl)-valine;N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-
• CAS NO: 137862-87-4
• Molecular Formula: C24H29N5O3
• Molecular Weight: 435.53
• Product Categories: Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 137862-87-4.mol
• Article Data: 51

Chemical Properties

• Melting Point: 108-110°C
• Boiling Point: 684.9°C at 760 mmHg
• Flash Point: 368°C
• Appearance: /
• Density: 1.212g/cm³
• Vapor Pressure: 1.06E-19mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.56±0.10(Predicted)
• CAS DataBase Reference: valsartan(CAS DataBase Reference)
• NIST Chemistry Reference: valsartan(137862-87-4)
• EPA Substance Registry System: valsartan(137862-87-4)

Safety Data

• Hazardous Substances Data: 137862-87-4(Hazardous Substances Data)

Usage

Description

Valsartan, also known as ent-Valsartan, is the (R)-enantiomer of Valsartan (V095750). It is a white to off-white solid with specific chemical properties that make it useful in various applications.

Uses

Used in Pharmaceutical Industry:
Valsartan is used as an active pharmaceutical ingredient for the treatment of hypertension (high blood pressure). It functions as an angiotensin II receptor blocker, which helps in relaxing blood vessels and reducing blood pressure.
Used in Cardiovascular Applications:
In the field of cardiology, valsartan is utilized as a therapeutic agent for the management of heart failure and post-myocardial infarction (heart attack). Its ability to block angiotensin II receptors aids in improving heart function and reducing the risk of further cardiovascular events.
Used in Research and Development:
Valsartan is also used as a research compound in the development of new drugs and therapies related to hypertension and cardiovascular diseases. Its chemical properties and mechanism of action provide valuable insights for scientists working on novel treatments for these conditions.

InChI:InChI=1/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1

Upstream product

• 2042-37-7 o-cyanobromobenzene 
• 137863-20-8 (S)-N-(1-benzyloxycarbonyl-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine 
• 676129-92-3 desvaleroyl valsartan 
• 638-29-9 n-valeryl chloride 
• 867022-57-9 (S)-2-[(4-bromo-benzyl)-pentanoyl-amino]-3-methyl-butyric acid 
• 943019-61-2 N-[4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl-4-yl-methyl]-N-pentanoyl-L-valinate 
• 143945-72-6 N-trityl-5-(2-bromophenyl)tetrazole 
• 137863-17-3 methyl N-((2’-(1H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate 
• 1301606-95-0 {2'-[1-(o-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}-methanol 
• 1307853-49-1 C₂₂H₁₉BrN₄O 
• 1307853-60-6 C₃₄H₃₅N₅O₃ 
• 1301606-96-1 C₃₉H₄₃N₅O₄ 
• 512182-37-5 1-(o-methoxybenzyl)-5-phenyl-1H-tetrazole 
• 1301606-99-4 1-((2'-(1-(2-methoxybenzyl)-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)oxy)propan-2-one 

Downstream Products

• 58-93-5 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide 
• 137863-43-5 (S)-N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-(3-methyl-1-morpholino-1-oxobutan-2-yl)pentanamide 
• 1378237-69-4 (S)-2-((S)-2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanamido)-3-phenylpropanoic acid 

Relevant articles and documents

A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN

Disclosed herein is a process for the preparation and purification of Valsartan. The process according to the invention is capable of removing the toxic nitroamine impurities and providing substantially pure Valsartan.

Synthesis of 5-Substituted 1 H-Tetrazoles from Nitriles by Continuous Flow: Application to the Synthesis of Valsartan

An efficient continuous flow process for the synthesis of 5-substituted 1H-tetrazoles is described. The process involves the reaction between a polymer-supported triorganotin azide and organic nitriles. The polymer-supported organotin azide, which is in situ generated with a polystyrene-supported triorganotin alkoxide and trimethylsilylazide, is immobilized in a packed bed reactor. This approach is simple, fast (it takes from 7.5 to 15 min), and guarantees a low concentration of tin residues in the products (5 ppm). The process was developed to aryl-, heteroaryl-, and also alkylnitriles and was applied for the synthesis of valsartan, an angiotensin II receptor antagonist.

A trityl protecting group by removing method of preparing losartan medicine

The invention discloses a method for preparation of a Sartan drug by removal of a triphenylmethyl protective group. The method includes: under the catalysis of an insoluble weak acid, subjecting a Sartan prodrug and methanol to deprotection reaction, and after complete reaction, conducting aftertreatment to obtain the Sartan drug. The method has the characteristics of low cost, few side product, high quality product, and simple aftertreatment. At the same time, montmorillonite can be taken as insoluble weak acid, and the cost is low, thus being convenient for industrial production.